ESMO/ECCO to host combined meetings

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

LUGANO, Switzerland-The European Society for Medical Oncology (ESMO) and the European Cancer Organisation (ECCO) (Brussels) have united forces to host a co-branded biennial multidisciplinary partnership meeting to provide “the best and most updated scientific data for everyone working in cancer,” the two organizations announced in a press release.

LUGANO, Switzerland-The European Society for Medical Oncology (ESMO) and the European Cancer Organisation (ECCO) (Brussels) have united forces to host a co-branded biennial multidisciplinary partnership meeting to provide “the best and most updated scientific data for everyone working in cancer,” the two organizations announced in a press release.

The ECCO Congress, which takes place every 2 years, will become a joint ECCO-ESMO Congress. The first congress will be September 20-24, 2009, in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years. In the intervening even-numbered years, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, September 12-16 in Stockholm.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content